


## PHARMACEUTICAL 2017

## Allergan plc Rank 24 of 313





## PHARMACEUTICAL 2017



## Allergan plc Rank 24 of 313

The relative strengths and weaknesses of Allergan plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Allergan plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 234% points. The greatest weakness of Allergan plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 158%, being 574% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	17,857,900
Cost of Goods Sold	0
Intangible Assets	108,974,700
Liabilities, Current	7,874,700
Liabilities, Non-Current	1,085,000
Other Assets	542,400
Other Compr. Net Income	-550,400
Other Expenses	10,449,500
Other Liabilities	43,826,100
Other Net Income	14,908,000
Property and Equipment	1,611,300
Research and Development	2,575,700
Revenues	14,570,600
Selling, General and Administrative Expense	1,473,900

Output Variable	Value in 1000 USD
Assets	128,986,300
Liabilities	52,785,800
Expenses	14,499,100
Stockholders Equity	76,200,500
Net Income	14,979,500
Comprehensive Net Income	14,704,300
Economic Capital Ratio	158%